Finoriq research workspace
Aprea Therapeutics, Inc. (APRE) SEC Filings & Filing Highlights
Review SEC filings, SEC-derived company events, filing highlights, source excerpts, and material disclosure activity for Aprea Therapeutics, Inc. (APRE).
Company Snapshot
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.
- Company
- Aprea Therapeutics, Inc. (APRE)
- Ticker
- APRE
- Market Cap
- $8.4M
- Latest Price
- $0.677
- Industry
- Biotech & Pharma
Aprea Therapeutics, Inc. (APRE) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Aprea Therapeutics, Inc. (APRE).
| Event | Form | Date |
|---|---|---|
| At the 2026 annual meeting of stockholders of Aprea Therapeutics, Inc. held on June 16, 2026, t...At the 2026 annual meeting of stockholders (the “Annual Meeting”) of Aprea Therapeutics, Inc. (the “Company”) held on June 16, 2026, the fo... | 8-K5.07 | 2026-06-17 |
| Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate UpdateAprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update | 8-K8.01 | 2026-05-13 |
| Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate UpdateAprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update | 8-K2.02 | 2026-05-13 |
| Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private PlacementAprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement | 8-K7.01 | 2026-04-01 |
| Aprea Therapeutics Announces Oversubscribed $30 Million Private PlacementAprea Therapeutics Announces Oversubscribed $30 Million Private Placement | 8-K8.01 | 2026-03-30 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.